Last updated on March 2018

A Study Evaluating MM-310 in Patients With Solid Tumors


Brief description of study

MM-310 is a liposomal formulation of a docetaxel prodrug that targets the EphA2 receptor on cancer cells. Docetaxel is an approved chemotherapeutic drug.This study is a Phase 1 open-label study of MM-310 in patients with solid tumors. In the first part of the study, MM-310 will be assessed as a monotherapy until a maximum tolerated dose (MTD) is established. After an MTD of MM-310 as a monotherapy is established, an expansion cohort and MM-310 in combination with other therapies will be assessed.

Clinical Study Identifier: NCT03076372

Find a site near you

Start Over

Honor Health

Scottsdale, AZ United States
  Connect »

University California San Francisco

San Francisco, CA United States
  Connect »

Mayo Clinic

Rochester, MN United States
  Connect »

Duke University

Durham, NC United States
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.